Senior Medical Director – Clinical Development

United States

Apply with AI Apply

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, HealthcareIndustries

Requirements

Candidates must possess an MD or equivalent degree and have at least 5 years of experience in pharmaceutical or biotech clinical development, specifically within oncology solid tumors. Radiopharmaceutical experience is preferred, and experience in oncology drug development or sub-specialty training in oncology is required. The role involves approximately 30% domestic and international travel, with potential for evening and weekend work.

Responsibilities

The Senior Medical Director will be responsible for the clinical development of targeted radiopharmaceuticals for solid tumors, including IND preparation, regulatory interactions, and filing document preparation. They will design and execute Phase 1-3 clinical trials, provide medical monitoring, and guide the clinical development strategy. This includes leading internal project teams, collaborating with investigators and CROs, writing protocols and reports, overseeing data review, and serving as the clinical lead for regulatory interactions. The role also involves supervising junior staff and establishing relationships with thought leaders.

Skills

Clinical Development

IND preparation

Regulatory Authority Interactions

Regulatory Filing

Phase 1-3 Clinical Trials

Medical Monitoring

Radiopharmaceuticals

Solid Tumors

Biotechnology

Drug Development

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free